TOPLINE: Belimumab combined with standard therapy demonstrated significant improvements in mucocutaneous symptoms in patients with systemic lupus erythematosus (SLE) compared with placebo with standard therapy, with benefits maintained through week 52. Patients with high disease activity and serological activity at baseline showed considerable improvement. METHODOLOGY: Researchers conducted a post hoc analysis of data from five […]
The post Belimumab Shows Efficacy for Mucocutaneous Symptoms in SLE first appeared on News Health.
Author : News Health
Publish date : 2025-03-24 12:00:00
Copyright for syndicated content belongs to the linked Source.